Sunesis Pharmaceuticals (SNSS) Trading Down 11.8%

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) was down 11.8% on Tuesday . The stock traded as low as $0.48 and last traded at $0.45. Approximately 12,435 shares were traded during mid-day trading, a decline of 92% from the average daily volume of 147,854 shares. The stock had previously closed at $0.51.

Separately, Zacks Investment Research raised shares of Sunesis Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $2.50 target price for the company in a research report on Wednesday, October 10th. Three research analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. Sunesis Pharmaceuticals presently has an average rating of “Buy” and an average target price of $3.75.

The stock has a market cap of $33.76 million, a price-to-earnings ratio of -0.34 and a beta of 2.04.

Sunesis Pharmaceuticals (NASDAQ:SNSS) last announced its quarterly earnings data on Monday, November 5th. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.04. Equities analysts predict that Sunesis Pharmaceuticals, Inc. will post -0.82 EPS for the current year.

A hedge fund recently raised its stake in Sunesis Pharmaceuticals stock. Millennium Management LLC lifted its holdings in shares of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) by 594.4% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 106,599 shares of the biopharmaceutical company’s stock after buying an additional 91,248 shares during the period. Millennium Management LLC owned 0.31% of Sunesis Pharmaceuticals worth $290,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 44.15% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Sunesis Pharmaceuticals (SNSS) Trading Down 11.8%” was first reported by Community Financial News and is owned by of Community Financial News. If you are reading this news story on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this news story can be viewed at

About Sunesis Pharmaceuticals (NASDAQ:SNSS)

Sunesis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. Its lead program is vecabrutinib, a non-covalently binding inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial in B-cell malignancies.

Featured Story: Coverage Ratio

Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit